GlassScriptPhysician profile
Hugo B Fonseca
NPI 1841519980
$22,588.27
in general payments reported to CMS, 2019-2025
43 companies · $5,354 in 2025
The $5,354 reported for 2025 was more than what 86% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $1,026 · 2021: $1,882 · 2022: $4,652 · 2023: $4,569 · 2024: $4,787 · 2025: $5,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,570.39 |
| Education | $139.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,695.50 | 2019-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $2,313.77 | 2020-2025 | Cimzia, Bimzelx |
| Abbvie INC. | $2,283.19 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,952.14 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $1,805.47 | 2021-2025 | Tremfya, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $1,101.16 | 2021-2025 | Saphnelo |
| Aurinia Pharma U.S., INC. | $1,095.11 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $1,088.22 | 2019-2025 | |
| Lilly USA, LLC | $1,059.29 | 2019-2025 | Taltz |
| Pfizer INC. | $1,055.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $678.80 | 2020-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $588.71 | 2019-2025 | Orencia |
| Radius Health, INC. | $530.90 | 2019-2025 | Tymlos |
| Horizon Therapeutics Plc | $506.10 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $328.81 | 2023-2024 | Purified Cortrophin Gel, Sovuna |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $275.09 | 2022-2025 | |
| Genentech USA, INC. | $224.47 | 2022-2025 | Actemra, Gazyva, Rituxan |
| Alvogen INC | $217.13 | 2022-2025 | Teriparatide |
| Octapharma USA, INC. | $211.65 | 2022-2025 | Octagam Immune Globulin (Human) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.90 | 2020-2025 | Ofev |
| Organon LLC | $193.10 | 2021-2025 | Nexplanon, Renflexis, Hadlima |
| Depuy Synthes Sales INC. | $145.23 | 2022-2024 | Orthovisc, Monovisc |
| Alexion Pharmaceuticals, INC. | $127.57 | 2021-2023 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $117.43 | 2021-2023 | Opsumit |
| Sobi, INC | $104.52 | 2020-2025 | |
| Invivyd INC | $71.73 | 2025 | Pemgarda |
| Mylan Institutional INC. | $69.07 | 2023 | Hulio |
| Grt US Holding, INC. | $63.75 | 2021-2022 | |
| Kyowa Kirin, INC. | $62.34 | 2023-2024 | Crysvita |
| Hikma Pharmaceuticals USA | $58.71 | 2021-2022 | |
| Pacira Therapeutics, INC. | $51.36 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $39.97 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $38.63 | 2023 | Arcalyst |
| Boston Scientific Corporation | $38.47 | 2023 | |
| Tonix Medicines, INC. | $35.38 | 2025 | Tonmya |
| Fresenius Kabi USA, LLC | $32.46 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $25.13 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $23.65 | 2022 | |
| Sandoz INC. | $20.84 | 2025 | Hyrimoz |
| Bioventus LLC | $19.62 | 2025 | Xcell |
| Pacira Pharmaceuticals Incorporated | $14.04 | 2023 | Iovera, Zilretta |
| Kowa Pharmaceuticals America, INC. | $13.38 | 2022 | |
| Tersera Therapeutics LLC | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugo Fonseca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.